Positive Hair Result in Patient using Tirzepatide 2/24/2025
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Wtf have we been doing for the last 30 years
Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.
community Clascoterone 5% solution infographic
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
community Will Pp405 be the Ozempic of bald Guys
PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.
community DHT levels and correlation to hair loss
The user experienced hair shedding after starting testosterone replacement therapy (TRT) and is considering using DHT blockers like finasteride or dutasteride to address potential DHT-related hair loss. Low ferritin levels due to frequent blood donations may also contribute to hair issues, and the user is working on stabilizing iron levels.
community Will PP405 be prohibitively expensive or will it be roughly the same as fin or min?
PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.
Related Research
6 / 6 results
research Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.
research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.
research Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.
research Rare and Underappreciated Causes of Polycystic Ovarian Syndrome
This review examines lesser-known factors contributing to polycystic ovarian syndrome and reports no new clinical results, emphasizing the need for further research into individualized treatment and prevention strategies.
research From Anti-Aging Medicine to Precision Healthspan Pharmacology: Evidence Domains, Monitoring Requirements, and Practical Boundaries
This source redefines anti-aging medicine as "precision healthspan pharmacology," suggesting that rather than just treating diseases or accepting aging, pharmacology should focus on expanding functional capacity across various health domains, while emphasizing the importance of fundamental physiological and psychosocial health factors.
research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.